SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Segment Information

Financial information for the company’s segments is as follows.

	Three months ended
	March 31,
(in millions)	2018		2017
Net sales
Americas	$	1,442	$	1,373
EMEA		724		631
APAC		511		471
Total net sales	$	2,677	$	2,475
Operating Income
Americas	$	566	$	533
EMEA		151		127
APAC		117		116
Total segment operating income	$	834	$	776

Operating Income to Income from Continuing Operations Reconciliation

The following is a reconciliation of segment operating income to income from continuing operations before income taxes per the condensed consolidated statements of income.

	Three months ended
	March 31,
(in millions)	2018			2017
Total segment operating income	$	834		$	776
Corporate and other		(402	)		(423	)
Total operating income		432			353
Net interest expense		12			14
Other (income) expense, net		(18	)		11
Income from continuing operations before income taxes	$	438		$	328

Net Sales by GBU

The following table represents net sales by GBU.

	Three months ended
	March 31,
(in millions)	2018		2017
Renal Care 1	$	868	$	789
Medication Delivery 2		676		664
Pharmaceuticals 3		496		427
Nutrition 4		223		212
Advanced Surgery 5		182		168
Acute Therapies 6		129		106
Other 7		103		109
Total Baxter	$	2,677	$	2,475

1 Renal Care includes sales of the company’s peritoneal dialysis (PD) and hemodialysis (HD) and additional dialysis therapies and services.

2 Medication Delivery includes sales of the company’s IV therapies, infusion pumps, administration sets and drug reconstitution devices.

3 Pharmaceuticals includes sales of the company’s premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4 Nutrition includes sales of the company’s parenteral nutrition (PN) therapies.

5 Advanced Surgery includes sales of the company’s biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6 Acute Therapies includes sales of the company’s continuous renal replacement therapies (CRRT) and other organ support therapies focused in the ICU.

7 Other includes sales primarily from the company’s pharmaceutical partnering business.